Entropy Neurodynamics (ASX:ENP) OCF Margin %: 0.00% (As of Dec. 2025)


What is Entropy Neurodynamics OCF Margin %?

Entropy Neurodynamics ASX:ENP -3.23% OCF Margin % is 0.00% as of Dec. 2025. The stock has 5 warning signs investors should review. Among 959 Biotechnology companies, Entropy Neurodynamics ranks worse than 104275.18% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Entropy Neurodynamics's Cash Flow from Operations for the six months ended in Dec. 2025 was A$-2.60 Mil. Entropy Neurodynamics's Revenue for the six months ended in Dec. 2025 was A$0.00 Mil. Therefore, Entropy Neurodynamics's OCF Margin % for the quarter that ended in Dec. 2025 was 0.00%.

As of today, Entropy Neurodynamics's current OCF Yield % is -10.90%.

The historical rank and industry rank for Entropy Neurodynamics's OCF Margin % or its related term are showing as below:


During the past 7 years, the highest OCF Margin % of Entropy Neurodynamics was -621.32%. The lowest was -8528.00%. And the median was -4574.66%.

ASX:ENP's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -66.52
* Ranked among companies with meaningful OCF Margin % only.

Entropy Neurodynamics OCF Margin % Related Terms

Entropy Neurodynamics OCF Margin % Historical Data

* Premium members only.

The historical data trend for Entropy Neurodynamics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Entropy Neurodynamics OCF Margin % Chart

Entropy Neurodynamics Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun25
OCF Margin %
Get a 7-Day Free Trial 0.00 0.00 -8,528.00 -621.32 0.00

Entropy Neurodynamics Semi-Annual Data
Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Dec24 Jun25 Dec25
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,219.61 0.00 0.00 0.00 0.00

Entropy Neurodynamics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Entropy Neurodynamics's OCF Margin for the fiscal year that ended in Jun. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=-7.77/0
= %

Entropy Neurodynamics's OCF Margin for the quarter that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-2.596/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Entropy Neurodynamics (ASX:ENP) has a OCF Margin % of 0.00% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Entropy Neurodynamics and its competitors. According to the industry distribution chart, Entropy Neurodynamics ranks #999999 out of 959 companies in the Biotechnology industry.
Is Entropy Neurodynamics' OCF Margin % too high?
Entropy Neurodynamics' current OCF Margin % is 0.00%. Based on the distribution chart, Entropy Neurodynamics ranks #999999 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Entropy Neurodynamics' OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Entropy Neurodynamics ranks #999999 out of 959 companies for OCF Margin %. This places Entropy Neurodynamics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Entropy Neurodynamics and its competitors. Entropy Neurodynamics's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entropy Neurodynamics stock overvalued right now?
Based on GuruFocus' analysis, Entropy Neurodynamics (ASX:ENP) is currently considered Fairly Valued. The stock's GF Value™ is A$0.03, compared to a current price of A$0.03 — trading right at its estimated fair value. The current OCF Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Entropy Neurodynamics (ASX:ENP), the current OCF Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Entropy Neurodynamics Business Description

Other Exchanges TYPTF:USA
Address 117 Camberwell Road,, Hawthorn East, Suite 1.01, Camberwell, Melbourne, VIC, AUS, 3123
Entropy Neurodynamics Ltd is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. The company's lead program is TRP-8803. TRP-8803 is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) with potential to alleviate numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe.